Clinical Trial Update: Reparixin in COVID-19 Pneumonia - Efficacy and Safety [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Reparixin in severe pneumonia (COVID-19) shows termination with posted results; phases 2 and 3 were conducted but terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Severe Pneumonia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-03-17